- Home
- NMRA vs LEGT Comparison
NMRA vs LEGT Comparison
Compare NMRA & LEGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRA
- LEGT
- Stock Information
- Founded
- NMRA 2019
- LEGT 2023
- Country
- NMRA United States
- LEGT United States
- Employees
- NMRA N/A
- LEGT N/A
- Industry
- NMRA
- LEGT
- Sector
- NMRA
- LEGT
- Exchange
- NMRA Nasdaq
- LEGT Nasdaq
- Market Cap
- NMRA 287.6M
- LEGT 269.6M
- IPO Year
- NMRA 2023
- LEGT 2024
- Fundamental
- Price
- NMRA $1.13
- LEGT $10.45
- Analyst Decision
- NMRA Buy
- LEGT
- Analyst Count
- NMRA 8
- LEGT 0
- Target Price
- NMRA $10.14
- LEGT N/A
- AVG Volume (30 Days)
- NMRA 1.3M
- LEGT 14.4K
- Earning Date
- NMRA 03-03-2025
- LEGT 01-01-0001
- Dividend Yield
- NMRA N/A
- LEGT N/A
- EPS Growth
- NMRA N/A
- LEGT N/A
- EPS
- NMRA N/A
- LEGT 0.32
- Revenue
- NMRA N/A
- LEGT N/A
- Revenue This Year
- NMRA N/A
- LEGT N/A
- Revenue Next Year
- NMRA N/A
- LEGT N/A
- P/E Ratio
- NMRA N/A
- LEGT $0.66
- Revenue Growth
- NMRA N/A
- LEGT N/A
- 52 Week Low
- NMRA $1.13
- LEGT $10.00
- 52 Week High
- NMRA $17.19
- LEGT $10.47
- Technical
- Relative Strength Index (RSI)
- NMRA 26.07
- LEGT N/A
- Support Level
- NMRA $1.13
- LEGT N/A
- Resistance Level
- NMRA $1.23
- LEGT N/A
- Average True Range (ATR)
- NMRA 0.12
- LEGT 0.00
- MACD
- NMRA 0.05
- LEGT 0.00
- Stochastic Oscillator
- NMRA 3.54
- LEGT 0.00
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has rapidly scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. The company expects to continue to progress in the development of its pipeline with the planned initiation of multiple clinical trials across its programs over the next 12 to 18 months, which supports numerous anticipated data readouts.
About LEGT Legato Merger Corp. III
Legato Merger Corp III is a blank check company.